Gilead Stops Pivotal Trial Early as New Leukemia Drug Demonstrates Strong ... Equities.com The monitoring committee made its recommendation based upon a predefined protocol showing “highly statistically significant efficacy” for the primary endpoint of progression-free survival in patients receiving a cocktail of idelalisib and rituximab ... |
